China’s Pharmaceutical Innovation Goes Global: Challenges and New Momentum In the first five months of 2025, China’s outbound innovative drug licensing deals have exceeded USD 45 billion, almost equaling the total for all of 2024. Behind this impressive figure lies…
Kidney cancer refers to the abnormal growth of cells within the kidneys, forming tumors that may spread to other parts of the body over time. What are the symptoms of kidney cancer? Recognizing early symptoms is crucial, as early detection…
August 29, 2025 – Beijing – The National Medical Products Administration (NMPA) of China has officially announced the approval of two Category 1 innovative drugs: Boehringer Ingelheim – Zongertinib Tablets Mechanism: Irreversible HER2 Tyrosine Kinase InhibitorIndication: Non-Small Cell Lung Cancer…
Ovarian cancer might sound scary, but understanding it doesn’t have to be complicated. How how to check for ovarian cancer at home? Simply put, ovarian cancer is when abnormal cells grow in the ovaries, the small organs in your lower…
What Causes Thyroid Cancer In Females? Thyroid cancer is one of the most common cancers affecting the endocrine system. It occurs more often in women than in men, especially during middle age. Understanding its causes, development, and preventive measures can…
Bladder cancer is a serious but often treatable condition when caught early. Recognizing the early symptoms can be life-saving. In this blog, Dengyue’ll walk you through what are the 5 warning signs of bladder cancer, explore its early symptoms, common…
— Reported by DengYueMed On June 24, 2024, Bio-Thera Solutions, Ltd. announced that its anti VEGF humanized monoclonal antibody BAT5906 has successfully met the primary endpoint in a pivotal Phase III clinical trial for the treatment of wet age-related macular…
Krazati (adagrasib) is a promising targeted therapy developed to treat certain cancers with a specific genetic mutation. If you or a loved one has been prescribed this medication, you may have many questions regarding its effectiveness, cost, approval status, and…
NEW YORK, April 8, 2025 (GLOBE NEWSWIRE) — TG Therapeutics, Inc.(TGTX) announced today that it will publish data on BRIUMVI® (ublituximab-xiiy) for the treatment of patients with relapsing multiple sclerosis (RMS). Michael S. Weiss, Chief Executive Officer and Chairman of…
Highlighted by Hong Kong DengYue Medicine What is Ensacove Ensartinib? Ensacove Ensartinib (X-396) is an advanced second-generation ALK tyrosine kinase inhibitor (TKI) designed to treat patients with ALK-positive non-small cell lung cancer (NSCLC). Developed to overcome resistance and limitations seen…
